PRNewsWire
21 May 2026, 19:33 UTC · 24w ago
Impact · against what's priced in
GeneDx (WGS) faces severe negative catalysts as a significant revenue guidance cut and lower reimbursement rates are compounded by a new securities fraud investigation. Teladoc (TDOC) and Olin (OLN) face marginal increased risk due to separate investigations by the same law firm.
No priced-in read yet
What the story claims
4 claims · scored −1 bearish … +1 bullish
GeneDx Holdings Corp. significantly reduced its full-year 2026 revenue guidance to $475M–$490M from a previous range of $540M–$555M.
So whatA substantial downward revision of annual revenue guidance typically triggers a sharp devaluation of the company's equity.
More negative than 99% of claims this week
Pomerantz LLP has launched an investigation into GeneDx for potential securities fraud or unlawful business practices.
Continue reading
5 related stories
The company slashed full-year revenue guidance to $475M–$490M from $540M–$555M and is now under investigation by Pomerantz LLP for potential securities fraud following a 49% stock price drop.
Read from the article alone
No priced-in read yet
Pomerantz Law Firm has launched an investigation into the company for potential securities fraud or unlawful business practices.
Read from the article alone
No priced-in read yet
Pomerantz Law Firm has launched an investigation into the company for potential securities fraud or unlawful business practices.
Read from the article alone
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More negative than 94% of claims this week
GeneDx reported that total revenue was approximately $12 million below expectations, partly due to lower-than-expected reimbursement rates for genomic testing.
More negative than 90% of claims this week
GeneDx's expected growth in exome and genome revenue was lowered to at least 20% from a previous target of 33% to 35%.
So whatSlowing growth rates in the company's primary high-value segments reduce the long-term valuation multiple.
More negative than 85% of claims this week
Which stocks this story touches
More negative than 98% of ticker scores this week
The company is facing a securities fraud investigation following a significant revenue guidance cut and a nearly 50% drop in stock price.
More negative than 92% of ticker scores this week
The company is mentioned as the subject of an investigation by Pomerantz Law Firm on behalf of investors.
More negative than 92% of ticker scores this week
The company is mentioned as the subject of an investigation by Pomerantz Law Firm on behalf of investors.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
1h ago
+43.9%
Price is moving against the score
$64.36 vs $44.73 close before publication (May 20) · not market-adjusted
WGS chart →+45.2%
Price is moving against the score
$9.41 vs $6.48 close before publication (May 20) · not market-adjusted
TDOC chart →−31.4%
Price agrees with the score
$18.06 vs $26.31 close before publication (May 20) · not market-adjusted
OLN chart →
